Intellia Therapeutics lands non-dilutive OrbiMed debt facility up to $400M
Intellia Therapeutics secured a non-dilutive debt facility with OrbiMed for up to $400 million: $75 million funded upfront and $325 million tied to milestones, aimed at added strategic flexibility.
Intellia Therapeutics said it has secured a non-dilutive debt facility from OrbiMed, with $75 million funded upfront and an additional $325 million tied to milestones. The company said the financing is intended to provide strategic flexibility through anticipated value inflection points. CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
NASDAQ:NTLA, a leading biopharmaceutical company focused on revo…